4.7 Review

RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential

Journal

JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 15, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13045-022-01224-4

Keywords

m(6)A modification; ALKBH5; RNA demethylation; Cancer; Gene regulation; Therapeutic target

Funding

  1. National Natural Science Foundation of China [81872322]
  2. Zhejiang Key Research and Development Project [2020C03014]

Ask authors/readers for more resources

ALKBH5 is an RNA demethylase that modulates m(6)A modification and controls cell processes. It regulates gene expression by affecting multiple events in RNA metabolism and plays critical roles in various cancers.
RNA demethylase ALKBH5 takes part in the modulation of N-6-methyladenosine (m(6)A) modification and controls various cell processes. ALKBH5-mediated m(6)A demethylation regulates gene expression by affecting multiple events in RNA metabolism, e.g., pre-mRNA processing, mRNA decay and translation. Mounting evidence shows that ALKBH5 plays critical roles in a variety of human malignancies, mostly via post-transcriptional regulation of oncogenes or tumor suppressors in an m(6)A-dependent manner. Meanwhile, increasing non-coding RNAs are recognized as functional targets of ALKBH5 in cancers. Here we reviewed up-to-date findings about the pathological roles of ALKBH5 in cancer, the molecular mechanisms by which it exerts its functions, as well as the underlying mechanism of its dysregulation. We also discussed the therapeutic implications of targeting ALKBH5 in cancer and potential ALKBH5-targeting strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available